Adynxx, Inc. announced an agreement to develop an oral, non-hormonal drug therapy with the potential to address the underlying mechanisms of endometriosis and significantly improve upon the standard of care. Under the agreement, twoXAR will use its proprietary AI technology to identify a set of drug candidates with the potential to treat or prevent the recurrence of endometriosis and associated symptoms. Adynxx will select candidates from this set to test for efficacy using in vivo models of endometriosis based on predetermined criteria. Following identification of one or more candidates based on those evaluated in vivo, Adynxx intends to conduct preclinical characterization work, IND-enabling work and clinical development. Further details of the agreement were not disclosed. Endometriosis is an inflammatory disease that affects 176 million women worldwide and is characterized by abnormal growth of endometrial-like tissue outside the uterus. It is associated with a range of symptoms including chronic pelvic pain, dysmenorrhea, dyspareunia, subfertility and hyperalgesia. Current treatment options consist of hormonal therapies, analgesics and surgery, with medications generally being the first and most common option. It is estimated that endometriosis will affect one in 10 women of reproductive age, with approximately 4.4 million women having been laparoscopically diagnosed in the US alone, making endometriosis one of the most common gynecologic disorders in the US.